ALK and non-small cell lung carcinoma: For advanced NSCLC, the current standard of care for first‐line treatment of stage IV epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)‐negative disease comprises platinum doublets, with carboplatin‐based doublet chemotherapy recommended for elderly patients (Planchard et al., 2018).